Investor Value Proposition

Trillium is developing the next-generation of cancer immunotherapies. Our lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a "do not eat" signal to macrophages. High expression of CD47 by tumor cells has been correlated with more aggressive disease and poor survival. SIRPαFc is initially being developed as a therapy for acute myeloid leukemia but also holds promise as a treatment for other hematological and solid tumors.

Recent Presentations

Thumb Date Download
Feb 24, 2017 ASCO-SITC 2017 839 KB
Dec 03, 2016 ASH 2016 Presentation 3.87 MB

Investor FAQ

Question:
Where can I find the current share price?

Answer:

The current share price can be found by searching for the ticker symbol “TRIL” at www.tmx.com and at www.nasdaq.com.

EMAIL ALERTS

Email Address: *
First Name:
Mailing Lists




 
Enter the code shown above.

Powered By Q4 Inc. 4.4.0.12